MetaVia Completes Last Patient Visit In Extended 24-Week Phase 1 Part 3A Study Of DA-1726
Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks
Follow the latest MetaVia Inc. (MTVA) news and market headlines alongside the live MTVA price. Stay informed on what's moving MTVA.
Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks
MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive preclinical data from a head-to-head study comparing DA-1726, a
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.73) by 5.48 percent. This is a 55.19 percent increase over losses of $(1.54) per share from the same
MetaVia reports positive Phase 1 data showing that once-weekly DA-1726 significantly reduces serum uric acid and liver fat.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to MTVA, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.